Evidence map›Paper›PMID 37513851›Full record

ArticlePharmaceuticals (Basel, Switzerland)2023

Comparison of Bevacizumab and Aflibercept for Suppression of Angiogenesis in Human Retinal Microvascular Endothelial Cells.

Amirfarbod Yazdanyar, Charles L Cai, Jacob V Aranda, Eric Shrier, Kay D Beharry

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Amirfarbod YazdanyarDepartment of Ophthalmology, State University of New York, Downstate Health Sciences University, Brooklyn, NY 11203, USA.ORCID 0000-0002-5393-5243
Charles L CaiDepartment of Ophthalmology, State University of New York, Downstate Health Sciences University, Brooklyn, NY 11203, USA.
Jacob V ArandaDepartment of Ophthalmology, State University of New York, Downstate Health Sciences University, Brooklyn, NY 11203, USA.
Eric ShrierDepartment of Pediatrics/Division of Neonatal-Perinatal Medicine, State University of New York, Downstate Health Sciences University, Brooklyn, NY 11203, USA.
Kay D BeharryDepartment of Ophthalmology, State University of New York, Downstate Health Sciences University, Brooklyn, NY 11203, USA.ORCID 0000-0002-4129-475X

Funding

Synergistic Pharmacologicjntervention for Prevention of ROP (SPIPROP STUDY)U54HD071594 · NICHD · SUNY DOWNSTATE MEDICAL CENTER · PI ARANDA, JACOB V · 2011 to 2015
$3.6M
Eunice Kennedy Shriver National Institute of Child Health and Human Development U54HD071594
6 · The paper itself

Abstract

Bevacizumab (Avastin) is a vascular endothelial growth factor (VEGF) inhibitor that is widely used for aggressive posterior retinopathy of prematurity (APROP). Its use is associated with multiple adverse effects. Aflibercept (Eylea) is a VEGFR-1 analogue that is approved for ocular use, but its efficacy for APROP is less studied. We tested the hypothesis that Eylea is as effective as Avastin for suppression of intermittent hypoxia (IH)-induced angiogenesis. Human retinal microvascular endothelial cells (HRECs) were treated with Avastin and low- or high-dose Eylea and exposed to normoxia, hyperoxia (50% O

Indexed as

angiogenesisantioxidantshuman retinal microvascular endothelial cellsintermittent hypoxiaNotchNotch signalingVEGF signaling

Identifiers

PMID37513851
PMCPMC10383229

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.